NantHealth IPO

6/2/2016

IPO

$91,000,000

The principal purposes of this offering are to obtain additional capital to support our operations, establish a public market for our common stock and facilitate our future access to the public capital markets. More specifically, we anticipate that we will use the net proceeds from this offering, together with our existing cash, for general corporate purposes, including to pay approximately $9.0 million to cover withholding taxes for the issuance of common stock to holders of phantom units that vest in connection with this offering under our Phantom Unit Plan (assuming the midpoint of the range set forth on the cover page of this prospectus), commercialize new solutions and product extensions and potentially pursue targeted acquisitions. We may use a portion of the net proceeds from this offering and our existing cash and cash equivalents to in-license, acquire or invest in complementary business, technologies, products or assets. However, we have no current plans, commitments or oblig

Publicly-held

Enterprise IT

2040 E Mariposa Ave.
El Segundo, CA 90245
USA

NANTHEALTH (Nasadaq: NH) solutions are advancing diagnostics to better identify and target specific disease characteristics; transforming clinical delivery with clinical data and promoting wellness for a healthier, happier world.